Year: 2024

4112 posts

CCTV+: Embarking on a Renewed Dialogue at Liangzhu Between Global Civilizations–The 'Liangzhu: A Dialogue across World Civilizations' Promotional Video and Documentary to Premier

BEIJING, Nov. 22, 2024 /PRNewswire/ — Exchanges make civilizations colorful, and mutual…

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

SHANGHAI, Nov. 22, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or…

Turfan Leads the Way: Electricity Drives Development of Smart Irrigation Demonstration Zone

TURFAN, China, Nov. 22, 2024 /PRNewswire/ — On November 19, State Grid…
Sungrow Strengthens Australian Market Presence with 1.7GWh of C&I Energy Storage Partnerships with Raystech and Solar Juice

Sungrow Strengthens Australian Market Presence with 1.7GWh of C&I Energy Storage Partnerships with Raystech and Solar Juice

SYDNEY, Nov. 22, 2024 /PRNewswire/ — Sungrow, the global leading PV inverter…

Global Times: Neo-Chinese cuisine: How China is reimagining its food heritage

BEIJING, Nov. 22, 2024 /PRNewswire/ — The concept of beauty has intrigued…

Turfan's Real-Time Power Response System Boosts Regional Tourism

TURFAN, China, Nov. 22, 2024 /PRNewswire/ — On November 19, State Grid…

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

ROCKVILLE, Md. and SUZHOU, China, Nov. 22, 2024 /PRNewswire/ — Ascentage Pharma…

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

ROCKVILLE, Md. and SUZHOU, China, Nov. 22, 2024 /PRNewswire/ — Ascentage Pharma…